Risankizumab | 合法藥品大搜索

Risankizumabisabiologicaltreatmentusedforpsoriasis,askindisorderinwhichskincellsformscalyredplaques,commonlyfoundontheelbows,knees,and ...

Risankizumab is a biological treatment[1] used for psoriasis[2], a skin disorder in which skin cells form scaly red plaques, commonly found on the elbows, knees, and lower back.

Risankizumab is an interleukin IL-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis[3] in adults who are candidates for systemic therapy[4] or phototherapy[5] [1].

Risankizumab was approved by the US Food and Drug Administration (FDA) in April 2019, in Japan in March 2019, and by the European Union in March 2019. Risankizumab has the trade name Skyrizi™ [AbbVie Inc., North Chicago, IL, USA] [1]. In January 2020, risankizumab was approved for use in Australia by the Therapeutics Goods Administration (TGA) and has been listed on the Pharmaceutical Benefits Scheme (PBS) for patients with chronic plaque psoriasis who meet the qualifying guideline...